Latest Headlines

Latest Headlines

Bristol-Myers pushes blockbuster cancer drug prospect into ASCO spotlight

BMS has high hopes for making BMS-936558 the latest pearl to add to its string of ASCO jewels.

Bristol-Myers grabs EU approval of key melanoma drug

As expected, the European Commission has approved Bristol-Myers Squibb's ($BMY) immunotherapy called Yervoy (ipilimumab) for melanoma that spreads to internal organs. And the company's European chief

BMS, Roche join forces and drugs on combo melanoma program

If you want to attack an aggressive killer like metastatic melanoma, it's best to target it from as many angles as possible. That's the approach that Roche is taking with its promising late-stage

FDA hands Bristol a blockbuster approval for breakthrough cancer drug

By the time the dust had settled on Friday's announcement that the FDA had approved Yervoy (ipilimumab) for melanoma, analysts were left clearly impressed by two key points: The FDA had extended an

FDA approves Bristol's Yervoy (ipilimumab) for melanoma

The FDA has approved Bristol-Myers Squibb's Yervoy (ipilimumab), a closely-watched new drug for advanced melanoma. The FDA delayed a decision on the drug in November after BMS submitted further

FDA nears deadline on closely-watched melanoma drug

All eyes are on the FDA as regulators face a Saturday deadline for their decision on Bristol-Myers Squibb's melanoma drug ipilimumab. With an average extended survival of four months, the therapy

Bristol's breakthrough melanoma drug delivers promising data in Ph3

With key analysts predicting regulatory approval later in the week for Bristol-Myers Squibb's ($BMS) ipilimumab--a breakthrough immunotherapy cancer treatment--researchers delivered a fresh batch of

FDA delays decision on BMS cancer drug ipilimumab

Bristol-Myers Squibb ($BMS) has revealed that the FDA will require more time to review its BLA for ipilimumab, an investigational drug for the treatment of advanced melanoma. The agency has moved its

Benlysta, BMS melanoma drug win accelerated FDA review

Two of the most closely watched therapies now awaiting a final decision at the FDA won an accelerated regulatory review. Human Genome Sciences will have four months shaved off the usual review

BMS, Pfizer cancer drugs take starring roles at ASCO

Bristol-Myers Squibb's ipilimumab took the center ring at ASCO over the weekend, earning star billing for its promising data on melanoma. In a small trial, patients taking the drug lived a median of